Moderna称明年首季将供应至少1亿剂新冠疫苗
美国药厂Moderna(MRNA.US)表示,预计明年首季将在全球推出1亿至1.25亿剂新冠疫苗,当中8,500万至1亿剂将向美国提供,海外供应则为1,500万至2,500万剂。
另外,中国科兴生物的100万剂疫苗已抵达巴西,该款疫苗仍需得到巴西当局的批准联,预计科兴生物将在12月15日前公布疫苗的的临床测试数据。
圣保罗州州长表示,今个月将会收到科兴生物的600万剂疫苗,而到1月15日还将再收到4,000万剂。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.